ViiV Healthcare appoints Just:: Health PR

pharmafile | April 12, 2012 | News story | Medical Communications, Sales and Marketing HIV/AIDS, Just::, PR, ViiV 

ViiV Healthcare has appointed Just:: Health PR to work on an integrated political and public relations initiative that will engage politicians, healthcare professionals and patient groups.

ViiV specialises in developing and marketing HIV treatments, and is jointly owned by GlaxoSmithKline and Pfizer, who set up the standalone firm in 2009.

Just:: the London-based healthcare communications firm, has been awarded a brief to engage with the HIV community and policymakers, exploring options for service reconfiguration and building consensus about how to deliver world-class care.

Senior consultant Laura Chambers and new head of political relations Jon Spiers will lead the account. Chambers said: “We’re thrilled about this campaign, which will bring together voices from across the HIV sector to create a meaningful dialogue about how HIV services should look in the 21st century.”

Spiers said: “Given the financial pressures on the NHS and the ongoing debate around health service reforms, there couldn’t be a better time to think about how to deliver the best possible HIV services. It might not be easy or quick but it will be a hugely exciting challenge.”

More people are living with HIV in the UK than ever before and this year will see an estimated 100,000 people diagnosed with the disease in the country.

Thanks to advances in treatment and earlier diagnosis, HIV has become a chronic disease not an acute one, bringing a raft of new challenges including an ageing patient population and rising treatment costs.

Just:: works with a high number of pharma firms, including Allergan, Astellas UK, AstraZeneca, Bristol-Myers Squibb, Novartis, Pfizer, Sanofi and Shire, as well as a number of charity groups.

The team was established in 2006 and one of its first UK briefs was for Pfizer’s smoking cessation drug Champix.

Ben Adams

Related Content

landing-hero-images1

ViiV’s HIV drug Rukobia gets EC marketing authorisation

The European Commission (EC) has authorised ViiV Healthcare’s Rukobia (fostemsavir) 600mg extended-release tablets for use …

landing-hero-images1

ViiV gets EU approval for children’s HIV treatment

ViiV Healthcare, the global specialist HIV company, has received marketing authorisation from the European Commission …

1070297_viiv-healthcare-office-16

ViiV Healthcare announces authorisation of Europe’s first long-acting HIV injection

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline, has announced the authorisation …

Latest content